Study CONSORT diagram detailing the flow of control and Barrett's esophagus patients (cases) through the study.

<p>Patients who were unable to swallow the Cytosponge or whose Cytosponge sample failed processing were excluded from the study. Exact numbers of control and BE patients who successfully completed the study are noted.</p

Sensitivity of the Cytosponge-TFF3 in different groups of patients (full dataset in S2 and S3 Tables).

<p>C, Circumferential length; IMC, intramucosal carcinoma; LGD, low grade dysplasia; M, maximal length; NDBE, non-dysplastic BE.</p><p>Sensitivity of the Cytosponge-TFF3 in different groups of patients (full dataset in <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001780#pmed.1001780.s005" target="_blank">S2</a> and <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001780#pmed.1001780.s006" target="_blank">S3</a> Tables).</p

Modeling of Cytosponge-TFF3 testing and risk stratification in the primary care population with reflux symptoms.

<p>Extrapolation of findings to a hypothetical population of 10,000 individuals with reflux symptoms using a sensitivity and specificity of 79.9% and 92.4%, respectively, for the TFF3 screen, and a sensitivity and specificity of 86% (95% CI of 65%–96%) and 100% (95% CI of 94.6%–100%), respectively, for <i>TP53</i> mutation screening for detection of HGD. The assumed prevalence of BE was 3%. In patients found to be high risk, endoscopy within 6–8 wk would be recommended. For low-risk patients, a repeat Cytosponge-TFF3 test would be performed at an interval of several years (exact timing to be determined) in case they had become TP53 positive over this time period. In the TFF3-negative arm, the repeat Cytosponge testing might not be necessary. If it took place, repeat testing would be recommended within 6 to 8 wk of the delivery of the TFF3-negative results.</p

Clinical covariates have no impact on sensitivity and specificity of the test.

<p>Clinical covariates have no impact on sensitivity and specificity of the test.</p

TFF3 immunohistochemical staining of Cytosponge samples.

<p>TFF3 staining was performed on all Cytosponge samples to test the sensitivity and specificity of the Cytosponge-TFF3 test for diagnosing BE. TFF3 was scored in a binary fashion, with samples with one or more TFF3-positive goblet cells being classed as positive. Shown are immunohistochemical images illustrating examples of TFF3-negative and-positive staining at low magnification (100×) and high magnification (400×).</p

Demographics of the BEST2 Study patient cohorts.

<p>^aBE defined as endoscopically visible columnar-lined esophagus that measured at least 1 cm circumferentially or at least 3 cm in non-circumferential tongues (Prague classification ≥C1 or ≥M3).</p><p>^bSex ratio rounded to the nearest tenth.</p><p>n/a, not applicable.</p><p>Demographics of the BEST2 Study patient cohorts.</p